不同剂量阿托伐他汀治疗冠心病伴高脂血症的临床效果分析
2015-01-31王星
王星
不同剂量阿托伐他汀治疗冠心病伴高脂血症的临床效果分析
王星
作者单位: 473000河南省南阳市中心医院
Analysis the Clinical Effect on Different Doses of Atorvastatin in Treatment of Coronary Heart Disease With Hyperlipidemia
WANG Xing Nanyang Central Hospital in He’nan Province, Nanyang 473000, China
[Abstract]Objective To explore the clinical effect of different doses of atorvastatin in the treatment of coronary heart disease with hyperlipidemia. Methods Selected 62 cases of coronary heart disease with hyperlipidemia were randomly divided into control group and observation group, 31 cases in each group. The control group on the basis of routine treatment given atorvastatin of atorvastatin 20 mg/d, the observation group 40 mg/ d, and 3 months for a course of treatment, the effects of both drugs after a period of treatment of two groups of patients with blood lipid levels and cardiovascular adverse events occurring rate and adverse drug reactions. Results After treatment, the, LDL-C, TG and TC of the groups were decreased, the observation group was lower than the control group, P<0.05,
had difference statistically significance. In addition, the incidence of adverse cardiovascular events and adverse drug reactions in the observation group were also significantly different from the control group, P<0.05, had difference statistically significance. Conclusion High dose atorvastatin can reduce blood lipid levels in patients with coronary heart disease, prevention of adverse cardiovascular events, adverse drug reactions.
[Key words]Atorvastatin, Coronary heart disease, Hyperlipidemia, Efficacy analysis
冠心病是临床常见的心血管疾病之一,其发病率、致残率、病死率均较高,其中冠状动脉粥样硬化是主要诱因,早期诊断、及时治疗对改善患者预后具有重要意义[1]。近年来随着饮食结构的改变,冠心病合并高脂血症患者逐年增加,高脂血症是加速冠状动脉粥样硬化的主要诱因。因此,控制血脂水平可抑制动脉粥样硬化斑块内炎症反应,延缓粥样硬化的发展。阿托伐他汀能够有效保护心血管,患者的血脂水平,抗炎等作用,还具有降低血管再狭窄和心血管事件的发生率的作用[2]。观察不同剂量阿托伐他汀对冠心病患者的降脂作用及不良反应,具体报道如下。
1 资料与方法
1.1 一般资料
选取2014年2月~2015年4月我院收治的62例冠心病合并高脂血症患者作为研究对象,其中男性38例,女性24例;年龄47~81岁,平均年龄(61±3)岁;所有患者均经实验室检查及冠状动脉造影确诊为冠心病,并存在不同程度的高血脂症。将62例患者随机分为对照组和观察组,各31例,两组患者在年龄、性别、血脂水平、心功能、合并症等方面,P>0.05,差异不具有统计学意义。
1.2 治疗方法
所有患者均给予抗血小板聚集制剂、抗凝剂、β-受体阻滞剂、钙通道阻滞剂、硝酸盐类、ACEI类药物常规治疗,对照组在常规治疗的基础上给予阿托伐他汀20 mg/d,观察组在常规治疗的基础上给予阿托伐他汀40 mg/d,两组患者均1天1次,睡前服药。……
